REG - N4 Pharma PLC - Result of Broker Offer and Total Voting Rights

N4 PharmaAnnouncement

22/11/2022 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221122:nRSV2250Ha&default-theme=true

RNS Number : 2250H  N4 Pharma PLC  22 November 2022

22 November 2022

 

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Result of Broker Offer

 

Total Voting Rights

 

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, announces
that, further to the announcement made on 18 November 2022, the Broker Offer,
a facility to allow existing shareholders and other interested parties to
participate on the same terms to the Placing announced on 18 November 2022,
has now closed having raised a gross amount of £54,000, resulting in the
issue by the Company of an additional 2,700,000 new ordinary shares of 0.4
pence each ("Broker Offer Shares").

 

Broker Warrants

 

As part of its fee, TPI will be issued with warrants ("Broker Warrants") to
subscribe for 3,162,000 new ordinary shares exercisable at the Issue Price of
2 pence each, equivalent to 6 (six) per cent. of the gross aggregate value of
funds raised in the Placing and Broker Offer.  The Broker Warrants have a
term of 36 months from the date of admission of the Broker Offer Shares to
trading on AIM and are being issued under the Company's existing share
authorities.

 

Application for Admission

 

Application has been made for the Broker Offer Shares to be admitted to
trading on AIM ("Admission") and it is expected that Admission will take place
at 8.00 a.m. on or around 25 November 2022.  The Broker Offer Shares will
rank pari passu with the Company's existing ordinary shares.

 

Total Voting Rights

Following Admission of the Broker Offer Shares, the enlarged issued share
capital of the Company will comprise 233,780,349 ordinary shares of 0.4 pence
each.  The Company does not hold any ordinary shares in treasury.
Consequently, 233,780,349 is the figure which may be used by shareholders as
the denominator for the calculation by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure and Transparency Rules.

 

Terms and definitions in this notification are as defined in the notification
of 18 November 2022.

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 which has been incorporated into UK law by the European
Union (Withdrawal) Act 2018.  Upon the publication of this announcement via
Regulatory Information Service, this inside information is now considered to
be in the public domain.

 

Enquiries:

 

 N4 Pharma plc
 Nigel Theobald, CEO                                         Via IFC Advisory
 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                              Tel: +44(0)20 3470 0470
 Nominated Adviser and Joint Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

 Turner Pope Investments (TPI) Limited                       Tel: +44(0)20 3657 0050
 Joint Broker
 Andy Thacker

 James Pope

 IFC Advisory Ltd                                            Tel: +44(0)20 3934 6630
 Financial PR
 Graham Herring
 Zach Cohen

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity.  As these products progress through preclinical and
clinical programs, N4 Pharma will seek to receive up front payments, milestone
payments and ultimately royalty payments once products reach the market.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAEFAALPAFFA